Dermata Therapeutics, Inc. (DRMAW) — 10-Q Filings

10-Q Filings (6)

• Dermata Narrows Q3 Loss, Boosts Cash Amid Reverse Stock Split — Nov 14, 2025 Risk: high
  Dermata Therapeutics, Inc. (DRMAW) reported a net loss of $1,691,989 for the three months ended September 30, 2025, a significant improvement from the $3,173,15
• Dermata Narrows Losses, Boosts Cash Amid Going Concern Doubts — Aug 13, 2025 Risk: high
  Dermata Therapeutics, Inc. (DRMAW) reported a net loss of $4.00 million for the six months ended June 30, 2025, a significant improvement from the $5.96 million
• Dermata Therapeutics Files Q1 2025 10-Q Report — May 14, 2025 Risk: medium
  Dermata Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company, located at 3525 Del Mar Heights Rd., #322, San Diego, C
• Dermata Therapeutics Files Q3 2024 10-Q — Nov 13, 2024 Risk: high
  Dermata Therapeutics, Inc. filed a 10-Q for the period ending September 30, 2024. The company reported minimal revenue and significant operating expenses, resul
• Dermata Therapeutics Files Q2 2024 10-Q — Aug 7, 2024 Risk: medium
  Dermata Therapeutics, Inc. filed its Q2 2024 10-Q report on August 7, 2024, detailing its financial performance for the period ending June 30, 2024. The company
• Dermata Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 15, 2024 Risk: low
  Dermata Therapeutics, Inc. (DRMAW) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Dermata Therapeutics, Inc. filed a 10-Q report for the period e

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX